Cargando…
Cortical β-amyloid burden, neuropsychiatric symptoms, and cognitive status: the Mayo Clinic Study of Aging
Neuropsychiatric symptoms (NPS) are a risk factor for cognitive impairment and are associated with cortical β-amyloid (Aβ) deposition. We conducted a cross-sectional study derived from the ongoing population-based Mayo Clinic Study of Aging to examine the frequency of NPS among cognitively unimpaire...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6438979/ https://www.ncbi.nlm.nih.gov/pubmed/30923322 http://dx.doi.org/10.1038/s41398-019-0456-z |
_version_ | 1783407185854726144 |
---|---|
author | Krell-Roesch, Janina Vassilaki, Maria Mielke, Michelle M. Kremers, Walter K. Lowe, Val J. Vemuri, Prashanthi Machulda, Mary M. Christianson, Teresa J. Syrjanen, Jeremy A. Stokin, Gorazd B. Butler, Lesley M. Traber, Martin Jack, Clifford R. Knopman, David S. Roberts, Rosebud O. Petersen, Ronald C. Geda, Yonas E. |
author_facet | Krell-Roesch, Janina Vassilaki, Maria Mielke, Michelle M. Kremers, Walter K. Lowe, Val J. Vemuri, Prashanthi Machulda, Mary M. Christianson, Teresa J. Syrjanen, Jeremy A. Stokin, Gorazd B. Butler, Lesley M. Traber, Martin Jack, Clifford R. Knopman, David S. Roberts, Rosebud O. Petersen, Ronald C. Geda, Yonas E. |
author_sort | Krell-Roesch, Janina |
collection | PubMed |
description | Neuropsychiatric symptoms (NPS) are a risk factor for cognitive impairment and are associated with cortical β-amyloid (Aβ) deposition. We conducted a cross-sectional study derived from the ongoing population-based Mayo Clinic Study of Aging to examine the frequency of NPS among cognitively unimpaired (CU) and mild cognitive impairment (MCI) participants who either have normal (A−) or abnormal (A+) Aβ deposition. We also investigated whether combined presence of MCI and amyloid positivity (MCI/A+) is associated with greater odds of having NPS as compared to CU/A− (defined as reference group). Participants were 1627 CU and MCI individuals aged ≥ 50 years (54% males; median age 73 years). All participants underwent NPS assessment (Neuropsychiatric Inventory Questionnaire (NPI-Q); Beck Depression Inventory II (BDI-II); Beck Anxiety Inventory (BAI)) and (11)C-PiB-PET. Participants with an SUVR > 1.42 were classified as A+. We conducted multivariable logistic regression analyses adjusted for age, sex, education, and APOE ε4 genotype status. The sample included 997 CU/A−, 446 CU/A+, 78 MCI/A−, and 106 MCI/A+ persons. For most NPS, the highest frequency of NPS was found in MCI/A+ and the lowest in CU/A−. The odds ratios of having NPS, depression (BDI ≥ 13), or anxiety (BAI ≥ 8, ≥ 10) were consistently highest for MCI/A+ participants. In conclusion, MCI with Aβ burden of the brain is associated with an increased risk of having NPS as compared to MCI without Aβ burden. This implies that the underlying Alzheimer’s disease biology (i.e., cerebral Aβ amyloidosis) may drive both cognitive and psychiatric symptoms. |
format | Online Article Text |
id | pubmed-6438979 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-64389792019-04-01 Cortical β-amyloid burden, neuropsychiatric symptoms, and cognitive status: the Mayo Clinic Study of Aging Krell-Roesch, Janina Vassilaki, Maria Mielke, Michelle M. Kremers, Walter K. Lowe, Val J. Vemuri, Prashanthi Machulda, Mary M. Christianson, Teresa J. Syrjanen, Jeremy A. Stokin, Gorazd B. Butler, Lesley M. Traber, Martin Jack, Clifford R. Knopman, David S. Roberts, Rosebud O. Petersen, Ronald C. Geda, Yonas E. Transl Psychiatry Article Neuropsychiatric symptoms (NPS) are a risk factor for cognitive impairment and are associated with cortical β-amyloid (Aβ) deposition. We conducted a cross-sectional study derived from the ongoing population-based Mayo Clinic Study of Aging to examine the frequency of NPS among cognitively unimpaired (CU) and mild cognitive impairment (MCI) participants who either have normal (A−) or abnormal (A+) Aβ deposition. We also investigated whether combined presence of MCI and amyloid positivity (MCI/A+) is associated with greater odds of having NPS as compared to CU/A− (defined as reference group). Participants were 1627 CU and MCI individuals aged ≥ 50 years (54% males; median age 73 years). All participants underwent NPS assessment (Neuropsychiatric Inventory Questionnaire (NPI-Q); Beck Depression Inventory II (BDI-II); Beck Anxiety Inventory (BAI)) and (11)C-PiB-PET. Participants with an SUVR > 1.42 were classified as A+. We conducted multivariable logistic regression analyses adjusted for age, sex, education, and APOE ε4 genotype status. The sample included 997 CU/A−, 446 CU/A+, 78 MCI/A−, and 106 MCI/A+ persons. For most NPS, the highest frequency of NPS was found in MCI/A+ and the lowest in CU/A−. The odds ratios of having NPS, depression (BDI ≥ 13), or anxiety (BAI ≥ 8, ≥ 10) were consistently highest for MCI/A+ participants. In conclusion, MCI with Aβ burden of the brain is associated with an increased risk of having NPS as compared to MCI without Aβ burden. This implies that the underlying Alzheimer’s disease biology (i.e., cerebral Aβ amyloidosis) may drive both cognitive and psychiatric symptoms. Nature Publishing Group UK 2019-03-28 /pmc/articles/PMC6438979/ /pubmed/30923322 http://dx.doi.org/10.1038/s41398-019-0456-z Text en © The Author(s) 2019 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Krell-Roesch, Janina Vassilaki, Maria Mielke, Michelle M. Kremers, Walter K. Lowe, Val J. Vemuri, Prashanthi Machulda, Mary M. Christianson, Teresa J. Syrjanen, Jeremy A. Stokin, Gorazd B. Butler, Lesley M. Traber, Martin Jack, Clifford R. Knopman, David S. Roberts, Rosebud O. Petersen, Ronald C. Geda, Yonas E. Cortical β-amyloid burden, neuropsychiatric symptoms, and cognitive status: the Mayo Clinic Study of Aging |
title | Cortical β-amyloid burden, neuropsychiatric symptoms, and cognitive status: the Mayo Clinic Study of Aging |
title_full | Cortical β-amyloid burden, neuropsychiatric symptoms, and cognitive status: the Mayo Clinic Study of Aging |
title_fullStr | Cortical β-amyloid burden, neuropsychiatric symptoms, and cognitive status: the Mayo Clinic Study of Aging |
title_full_unstemmed | Cortical β-amyloid burden, neuropsychiatric symptoms, and cognitive status: the Mayo Clinic Study of Aging |
title_short | Cortical β-amyloid burden, neuropsychiatric symptoms, and cognitive status: the Mayo Clinic Study of Aging |
title_sort | cortical β-amyloid burden, neuropsychiatric symptoms, and cognitive status: the mayo clinic study of aging |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6438979/ https://www.ncbi.nlm.nih.gov/pubmed/30923322 http://dx.doi.org/10.1038/s41398-019-0456-z |
work_keys_str_mv | AT krellroeschjanina corticalbamyloidburdenneuropsychiatricsymptomsandcognitivestatusthemayoclinicstudyofaging AT vassilakimaria corticalbamyloidburdenneuropsychiatricsymptomsandcognitivestatusthemayoclinicstudyofaging AT mielkemichellem corticalbamyloidburdenneuropsychiatricsymptomsandcognitivestatusthemayoclinicstudyofaging AT kremerswalterk corticalbamyloidburdenneuropsychiatricsymptomsandcognitivestatusthemayoclinicstudyofaging AT lowevalj corticalbamyloidburdenneuropsychiatricsymptomsandcognitivestatusthemayoclinicstudyofaging AT vemuriprashanthi corticalbamyloidburdenneuropsychiatricsymptomsandcognitivestatusthemayoclinicstudyofaging AT machuldamarym corticalbamyloidburdenneuropsychiatricsymptomsandcognitivestatusthemayoclinicstudyofaging AT christiansonteresaj corticalbamyloidburdenneuropsychiatricsymptomsandcognitivestatusthemayoclinicstudyofaging AT syrjanenjeremya corticalbamyloidburdenneuropsychiatricsymptomsandcognitivestatusthemayoclinicstudyofaging AT stokingorazdb corticalbamyloidburdenneuropsychiatricsymptomsandcognitivestatusthemayoclinicstudyofaging AT butlerlesleym corticalbamyloidburdenneuropsychiatricsymptomsandcognitivestatusthemayoclinicstudyofaging AT trabermartin corticalbamyloidburdenneuropsychiatricsymptomsandcognitivestatusthemayoclinicstudyofaging AT jackcliffordr corticalbamyloidburdenneuropsychiatricsymptomsandcognitivestatusthemayoclinicstudyofaging AT knopmandavids corticalbamyloidburdenneuropsychiatricsymptomsandcognitivestatusthemayoclinicstudyofaging AT robertsrosebudo corticalbamyloidburdenneuropsychiatricsymptomsandcognitivestatusthemayoclinicstudyofaging AT petersenronaldc corticalbamyloidburdenneuropsychiatricsymptomsandcognitivestatusthemayoclinicstudyofaging AT gedayonase corticalbamyloidburdenneuropsychiatricsymptomsandcognitivestatusthemayoclinicstudyofaging |